Masafumi Kuroishi

Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan.

IMMD, Inc. provides drug discovery research for pharmaceutical companies. It identifies drug seeds by virtual screening, to select promising seeds and to optimize the seeds by minimum syntheses, based on estimated docking mode to the target. The firm also establishes a drug discovery method using software system for rational drug design based on 3-D structures of target proteins. Its business activities also include collaborative drug discovery researches, in-house drug discovery program, and drug seeds. The company was founded by Akiko Itai on March 16, 1995 and is headquartered in Tokyo, Japan.

CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan.

PharmaBio Corp. provides manufacturing and consulting company specializing in cellular and tissue based products. It offers of cell-based investigational new drugs, various contract testing and inspections including microbial safety testing of cells, specimen storage operations, development, manufacturing and marketing of clean room consumables and various equipment. The company was founded in April 1978 and is headquartered in Nagoya, Japan.

HuLA immune, Inc. is a Japanese company that provides immune cell therapy for cancer treatment. The company is based in Tokyo, Japan. The text in the company's description appears to be a mix of non-English languages, including British English and Japanese. It was founded in 2017 and the CEO is Yasuhiro Shindo.